TICKERNERD
Menu
IVVDIVVDHealthcare · Biotechnology

IVVD Stock Forecast: Invivyd, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$0.61
−5.91% on the day

The 3 Wall Street analysts covering Invivyd, Inc. hold a median 12-month price target of $10 — +1545.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 14 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$190.4M
Ticker Nerd rank
16 / 100
Median analyst target
$10
Analysts covering
3
Revenue$14.3M+21.2% y/y
Operating income−$45.8M
Net income−$44.4M
Free cash flow−$43.5M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−16.6%
1M
−31.9%
YTD
−75.4%
1Y
−62.7%
From 52W high
−78.9%
From 52W low
+13.6%
$0.54
$2.88
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IVVD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Invivyd, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
16 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
68
Quality
62
Growth
52
Value
39
Revisions
27
Momentum
21
Accruals
19
Issuance
12
Volatility
11

Size (68): Smaller than most of the companies we track.

Volatility (11): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IVVD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IVVD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26IVVDHigh $10Median $10Low $10

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $10Median $10High $10

The green dot is the last close — the median target sits +1545.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 Sept 2026BTIGReiteratesBuy$10
27 Aug 2026Cantor FitzgeraldReiteratesOverweight$10
27 Aug 2026Cantor FitzgeraldReiteratesOverweight—
7 July 2026BTIGReiteratesBuy$10
7 July 2026BTIGReiteratesBuy—
15 June 2026HC Wainwright & Co.ReiteratesBuy—
9 June 2026BTIGReiteratesBuy—
1 June 2026BTIGReiteratesBuy—
18 May 2026BTIGReiteratesBuy—
26 Feb 2026BTIGReiteratesBuy—
23 Dec 2025BTIGReiteratesBuy—
22 Dec 2025BTIGInitiatesBuy—
25 Nov 2025D. Boral CapitalDowngradeHold—
3 Nov 2025HC Wainwright & Co.MaintainsBuy—
31 Oct 2025HC Wainwright & Co.MaintainsBuy—
6 Oct 2025Cantor FitzgeraldInitiatesOverweight—
6 Oct 2025D. Boral CapitalMaintainsBuy—
27 Aug 2025HC Wainwright & Co.ReiteratesBuy—
25 Aug 2025D. Boral CapitalMaintainsBuy—
19 Aug 2025D. Boral CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IVVD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

IVVD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Invivyd, Inc. returned −62.7% against +17.5% for the S&P 500, dividends included.

IVVD vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200Jan 26Apr 26Jul 26Oct 26IVVDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

IVVD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Invivyd, Inc. (IVVD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.0×

Cheaper than 86% of US stocks

Price / sales
3.1×

Cheaper than 39% of US stocks

Price / book
1.0×

Cheaper than 71% of US stocks

EV / EBITDA
−0.3×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
21.2%

Higher than 70% of US stocks

Earnings growth (YoY)
21.2%

Higher than 59% of US stocks

Gross margin
91.1%

Higher than 97% of US stocks

Operating margin
−320.8%

Higher than 9% of US stocks

Net margin
−183.9%

Higher than 3% of US stocks

Returns & dividend
Return on equity
−95.9%

Higher than 14% of US stocks

Return on assets
−45.7%

Higher than 9% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Invivyd, Inc. (IVVD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Invivyd, Inc. has a market value of $190.4M and an enterprise value of $38.7M.

  • Revenue in the twelve months to 30 June 2026: $58.4M. The latest quarter grew 21.2% year on year.

  • Net income over the same four quarters: −$107.3M, a −183.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$109.7M.

  • Shares outstanding: 294.8M.

  • Trailing P/E: −2.0×; forward P/E: −1.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Invivyd, Inc. employs 122 people — $478K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Oct 2026

Data provided by Twelve Data

Peers

IVVD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
IVVDInvivyd, Inc.$190.4M
16
YARWYarrow Bioscience, Inc.$178.4M
59
TRDAEntrada Therapeutics, Inc.$176.6M
51
SIONSionna Therapeutics, Inc.$182.5M
28
ELDNEledon Pharmaceuticals, Inc.$182.8M
33
RNACCartesian Therapeutics, Inc.$185.8M
27
STROSutro Biopharma, Inc.$172.4M
77

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Invivyd, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IVVD news & analysis

Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome

GlobeNewsWire · 14 Oct 2026positive

Invivyd and the SPEAR Study Group announced the initiation of FLINTLOCK, a Phase 2 trial evaluating VYD2311 in people with Long COVID or Post-Vaccination Syndrome. The study will assess safety, tolerability, pharmacokinetics, and clinical efficacy.

Why it matters — The trial adds a clinical study of Invivyd’s VYD2311 in these conditions, which IVVD watchers may track for updates.

Invivyd Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 5 Oct 2026neutral

Invivyd announced that on October 1, 2026, it granted six newly hired non-executive employees options to purchase an aggregate of 157,500 shares of common stock as material inducements for their employment. The grants were made under Nasdaq Listing Rule 5635(c)(4) and pursuant to the Invivyd 2026 Inducement Plan.

Why it matters — The inducement grants signal new hiring at Invivyd and reflect standard employee compensation that IVVD watchers would track for governance and share-dilution context.

Invivyd's VYD2311 Phase III Study Meets Safety Goals, Eyes FDA Accelerated Approval

MarketBeat · 5 Oct 2026neutral

Invivyd reported topline results from the Phase III LIBERTY study of VYD2311, an investigational low-dose intramuscular monoclonal antibody intended to prevent COVID-19, and announced plans to pursue an accelerated-approval pathway with the U.S. Food and Drug Administration.

Why it matters — These results and the planned FDA accelerated-approval pathway represent a potential step forward in the regulatory progress of Invivyd's investigational COVID-19 prevention candidate.

Invivyd Outlines Accelerated Approval Submission Path with FDA for COVID-19 Antibody

Benzinga · 29 Sept 2026neutral

Invivyd announced topline results from its Phase 3 LIBERTY study of its investigational COVID-19 monoclonal antibody candidate. The company also outlined an accelerated approval submission path with the FDA for the antibody.

Why it matters — IVVD watchers would care because the Phase 3 results and FDA submission pathway mark a key regulatory milestone for the company's lead COVID-19 antibody candidate.

Invivyd, Inc. (IVVD) Discusses LIBERTY Phase III Topline Data and Next Steps for VYD2311 Regulatory Submission Transcript

Seeking Alpha · 29 Sept 2026neutral

Invivyd, Inc. executives discussed the LIBERTY Phase III topline data and outlined the next steps for the VYD2311 regulatory submission in a recent call. The discussion centered on the trial results and the company's planned path forward toward regulatory filing.

Why it matters — The LIBERTY Phase III results and the regulatory roadmap for VYD2311 are key milestones for Invivyd's pipeline development, so shareholders would follow these updates closely.

FAQ

Frequently asked questions about IVVD stock

What is the IVVD stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Invivyd, Inc. have a median 12-month price target of $10, with estimates ranging from $10 to $10. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IVVD stock a buy right now?

Of the 3 analysts covering Invivyd, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Invivyd, Inc. 16 out of 100 across roughly 4,600 US stocks as at 14 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IVVD?

As at 14 Oct 2026, Invivyd, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (68 of 100).

Will IVVD stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +1545.3% from the last close, and Ticker Nerd's factor model ranks Invivyd, Inc. 16 out of 100 as at 14 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IVVD stock forecast for 2030?

No analyst covering Invivyd, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IVVD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $10 to $10 over the next 12 months.

How has IVVD stock performed over the past year?

Invivyd, Inc. returned -62.7% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Invivyd, Inc. do?

Invivyd, Inc. Common Stock is the equity of Invivyd, a biopharmaceutical company focused on developing and commercializing monoclonal antibody therapies for the prevention and treatment of serious viral infectious diseases.

What is the latest news on IVVD?

The most recent item we track (GlobeNewsWire, 14 Oct 2026): "Invivyd and the SPEAR Study Group Announce Initiation of “FLINTLOCK” Phase 2 Study of VYD2311, a Monoclonal Antibody for the Potential Treatment of Long COVID or Post-Vaccination Syndrome". Invivyd and the SPEAR Study Group announced the initiation of FLINTLOCK, a Phase 2 trial evaluating VYD2311 in people with Long COVID or Post-Vaccination Syndrome. The study will assess safety, tolerability, pharmacokinetics, and clinical efficacy.

Company

About Invivyd, Inc.

Invivyd, Inc. Common Stock is the equity of Invivyd, a biopharmaceutical company focused on developing and commercializing monoclonal antibody therapies for the prevention and treatment of serious viral infectious diseases. The company’s current work centers on antibody-based solutions for COVID-19 and other respiratory viruses, supported by a proprietary platform that combines viral surveillance, predictive modeling, and antibody engineering. Its marketed and clinical-stage programs include PEMGARDA (pemivibart) and additional antibody candidates being developed for viral threats such as COVID-19, RSV, and measles. Invivyd serves the healthcare and biotechnology markets by advancing specialized biologic products designed for patients with limited preventive or treatment options, particularly immunocompromised populations. The company is headquartered in New Haven, Connecticut.

CEO Mr. Marc William Elia · 122 employees · United States · https://www.invivyd.com